Title:The Role of Kallikrein 7 in Tumorigenesis
Volume: 29
Issue: 15
Author(s): Fengyi Xiang, Yueqing Wang, Chunyu Cao, Qingyun Li, Hao Deng, Jun Zheng, Xiaowen Liu*Xiao Tan*
Affiliation:
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Medical College, China Three
Gorges University, Yichang, 443003, P.R. China
- Hubei Key Laboratory of Tumor Microenvironment and Immunotherapy, Medical College, China Three
Gorges University, Yichang, 443003, P.R. China
Keywords:
Kallikrein 7, therapeutic target, tumour development, cell signal pathway, Inhibitors, cancer treatment.
Abstract: Kallikrein 7 (KLK7) is a secreted serine protease with chymotrypsic protease
activity. Abnormally high expression of KLK7 is closely related to the occurrence and
development of various types of cancer. Therefore, KLK7 has been identified as a potential
target for cancer drug development design in recent years. KLK7 mediates various biological
and pathological processes in tumorigenesis, including cell proliferation, migration,
invasion, angiogenesis, and cell metabolism, by hydrolyzing a series of substrates
such as membrane proteins, extracellular matrix proteins, and cytokines. This review
mainly introduces the downstream cell signaling pathways involved in the activation of
KLK7 and its substrate-related proteins. This review will not only help us to better understand
the mechanisms of KLK7 in regulating biological and pathological processes of
cancer cells but also lay a solid foundation for the design of inhibitors targeting KLK7.